PULMOZYME sol inhal 2.5 mg/2.5 ml 30 amp
7680526230148
CH-52623
R05CB13
03.02.0.
Reimbursement limitations:
PULMOZYME
Mucoviscidose.
1 / 3
google
Details
- Product number
- 5262301
- CPT
- -
- Packaging group
- 5 x 6
- Unit
- Ampulle(n)
- Composition
- dornasum alfa 2.5 mg, natrii chloridum, calcii chloridum dihydricum, aqua ad iniectabile ad solutionem pro 2.5 ml.
Articles (1)
Pulmozyme, Inhalationslösung
Inhalationslösung
5 x 6
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
2.5 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 761.00
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
15/03/1995
Authorization holder
Roche Pharma (Schweiz) AG
4058 Basel
Authorization information
- Swissmedic authorization number
- 52623
- Drug name
- Pulmozyme, Inhalationslösung
- Galenic form
- LSVE
- ATC Code
- R05CB13
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 28/04/1994
- Authorization expiration date
- 31/12/9999
- IT number
- 03.02.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- PULMOZYME sol inhal 2.5 mg/2.5 ml 30 amp
- Description (DE)
- PULMOZYME Inhal Lös 2.5 mg/2.5 ml 30 Amp
- Market launch
- 28/04/1994
- Narcotic (BTM)
- No